Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 3, 1996, Pages 774-782

  Fisherman, J S ^a   Cowan, K H ^a   Noone, M ^a   Denicoff, A ^a   Berg, S ^a   Poplack, D ^a   Balis, F ^a   Venzon, D ^a   McCabe, M ^a   Goldspiel, B ^a   Chow, C ^a   Ognibene, F P ^a   O'Shaughnessy, J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 9044224027     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.3.774     Document Type: Article

References (32)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Reichman BS, Siedman AD, Crown JPA, et al: Paclitaxel and recombinant human granulocyte-colony stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
3. Jones RB, Holland JF, Bhardwaj S, et al: A phase I-II study of intensive dose Adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
4. Hahn SM, Liebmann JE, Cook J, et al: Taxol in combination with doxorubicin or etoposide. Cancer 72:2705-2711, 1993
5. Lopes NM, Adams EG, Pitts TW, et al: Cell kill kinetics and cell cycle effects of Taxol on human or hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 2993
6. Liebmann J, Cook J, Lipschultz C, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104-1109, 1993
7. Wilson WH, Berg SL, Bryant G, et al: Paclitaxel in doxorubicin or mitoxantrone refractory breast cancer: A phase I/II trial of 96 hour infusion. J Clin Oncol 12:1621-1629, 1994
8. Gupta RS: Cross-resistance of vinblastine and taxol resistant mutants of chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep 69:515-521, 1985
9. Horwitz SB, Lothstein L, Mellado W, et al: Taxol: Mechanisms of action and resistance. Ann NY Acad Sci 466:733-744, 1986
10. Horton JK, Thimmaiah KN, Houghton JA, et al: Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmcol 38:1727-1736, 1989
11. Lai G-M, Chen Y-N, Mickley LA, et al: P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 49:696-703, 1991
12. Kohn EC, Sarosy G, Bicher A, et al: Dose-intense Taxol: High response rate in patients with platinum-resistant ovarian cancer. J Natl Cancer Inst 86:18-24, 1994
13. Arbuck SG, Canetta R, Onetto N, et al: Current dosage and schedule issues in the development of paclitaxel (Taxol). Semin Oncol 20:31-39, 1993 (suppl 3)
14. 2 dose in combination with granulocyte colony-stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
15. Dobbs N, James C: Estimation of doxorubicin and doxorubicinol by high performance liquid chromatography and advanced automated sample processor. J Chromatogr Biomed Appl 420:184-188, 1987
16. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994
17. Pestalozzi BC, Sotos GA, Choyke PL, et al: Typhlitis resulting from treatment with Taxol and doxorubicin in patients with metastatic breast cancer. Cancer 17:1797-1800, 1993
18. Legha SS, Benjamin RS, Mackay B, et al: Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 49:1762-1766, 1982
19. Bielack SS, Erttmann R, Winkler K, et al: Doxorubicin: Effect of different schedules on toxicity and anti-tumor efficacy. Eur J Cancer Clin Oncol 25:873-882, 1989
20. Spriggs DR, Tondini C: Taxol administered as a 120-hour infusion. Invest New Drugs 10:275-278, 1992
21. Hruban RH, Yardley JH, Donehower RC, et al: Taxol toxicity: Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer 63:1944-1950, 1989
22. Holmes FA, Valero V: Taxol in the treatment of breast cancer, in Maguire WP, Rowinsky EK (eds): Taxol in Cancer Treatment. New York, NY, Dekker, 1994 (in press)
23. Sledge GW Jr, Robert N, Sparano JA, et al: Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: The Eastern Cooperative Oncology Group experience. Semin Oncol 21:15-18, 1994 (suppl 8)
24. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor activity and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995
25. Peereboom DM, Donehower RC, Eisenhauer EA, et al: Successful re-treatment with Taxol after major hypersensitivity reactions. J Clin Oncol 11:885-890, 1993
26. Rowinsky EK, McGuire WP, Guarnieri T, et al: Cardiac disturbances during the administration of Taxol. J Clin Oncol 9:1704-1712, 1991
27. O'Shaughnessy JA, Denicoff AM, Venzon DJ, et al: A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients. Ann Oncol 5:709-716, 1994
28. Waud WR, Schmid SM, Plowman J: In vitro and in vivo combination chemotherapy evaluations of Taxol with doxorubicin or topotecan. Second National Cancer Institute Workshop on Taxol and Taxus. Arlington, VA, National Cancer Institute, September 23-24, 1992
29. Rose WC: Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies. Monogr Natl Cancer Inst 15:47-53, 1993
30. LoRusso P, Demchik U, Plowman J, et al: Preclinical activity and toxicity of Taxol combinations. Proc Am Assoc Cancer Res 34:A1794, 1993 (abstr)
31. Baral E, Aver G: In vitro effect of doxorubicin on non-proliferating and proliferating epithelial cells. Int J Radiat Oncol Biol Phys 19:963-965, 1990
32. Hug V, Johnston D, Finers M, et al: Use of growth-stimulating hormones to improve the in vitro therapeutic index of doxorubicin for human breast tumors. Cancer Res 46:147-152, 1986